Literature DB >> 26626552

[ESC guidelines 2015 for ventricular arrhythmias and prevention of sudden cardiac death. What is new?].

T Fink1, K H Kuck1, A Metzner2.   

Abstract

The new European Society of Cardiology (ESC) guidelines for the management of patients with ventricular arrhythmia and the prevention of sudden cardiac death, recently published at the annual ESC meeting in London, contain an extensive update of the recommendations for the diagnostics, drug therapy, interventional and device therapy of ventricular arrhythmia. The new recommendations for implantable cardioverter defibrillator (ICD) treatment for primary and secondary prophylaxis of sudden cardiac death can be seen as a focused update of the previously published guidelines. Pre-existing recommendations for catheter ablation of ventricular arrhythmias have been partly extensively expanded with respect to the results of recent clinical trials. The guideline committee also adapted their recommendations regarding the hereditary arrhythmia syndromes to the 2013 consensus report of the American Heart Association (AHA), the European Heart Rhythm Association (EHRA) and the Asia Pacific Heart Rhythm Society (APHRS).

Entities:  

Keywords:  Catheter ablation; Implantable cardioverter defibrillator; Sudden cardiac death; Tachycardia; Ventricular arrhythmia

Mesh:

Year:  2015        PMID: 26626552     DOI: 10.1007/s00059-015-4380-6

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  47 in total

1.  Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest : the Cardiac Arrest Study Hamburg (CASH).

Authors:  K H Kuck; R Cappato; J Siebels; R Rüppel
Journal:  Circulation       Date:  2000-08-15       Impact factor: 29.690

2.  Rationale and design of the PRAETORIAN trial: a Prospective, RAndomizEd comparison of subcuTaneOus and tRansvenous ImplANtable cardioverter-defibrillator therapy.

Authors:  Louise R A Olde Nordkamp; Reinoud E Knops; Gust H Bardy; Yuri Blaauw; Lucas V A Boersma; Johannes S Bos; Peter Paul H M Delnoy; Pascal F H M van Dessel; Antoine H G Driessen; Joris R de Groot; Jean Paul R Herrman; Luc J L M Jordaens; Kirsten M Kooiman; Alexander H Maass; Mathias Meine; Yuka Mizusawa; Sander G Molhoek; Jurjen van Opstal; Jan G P Tijssen; Arthur A M Wilde
Journal:  Am Heart J       Date:  2012-05       Impact factor: 4.749

3.  Design and results of the antiarrhythmics vs implantable defibrillators (AVID) registry. The AVID Investigators.

Authors:  J L Anderson; A P Hallstrom; A E Epstein; S L Pinski; Y Rosenberg; M O Nora; D Chilson; D S Cannom; R Moore
Journal:  Circulation       Date:  1999-04-06       Impact factor: 29.690

4.  Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone.

Authors:  S J Connolly; M Gent; R S Roberts; P Dorian; D Roy; R S Sheldon; L B Mitchell; M S Green; G J Klein; B O'Brien
Journal:  Circulation       Date:  2000-03-21       Impact factor: 29.690

5.  Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.

Authors:  Stuart J Connolly; Paul Dorian; Robin S Roberts; Michael Gent; Steven Bailin; Eric S Fain; Kevin Thorpe; Jean Champagne; Mario Talajic; Benoit Coutu; Gerian C Gronefeld; Stefan H Hohnloser
Journal:  JAMA       Date:  2006-01-11       Impact factor: 56.272

6.  Outcomes in catheter ablation of ventricular tachycardia in dilated nonischemic cardiomyopathy compared with ischemic cardiomyopathy: results from the Prospective Heart Centre of Leipzig VT (HELP-VT) Study.

Authors:  Borislav Dinov; Lukas Fiedler; Robert Schönbauer; Andreas Bollmann; Sascha Rolf; Christopher Piorkowski; Gerhard Hindricks; Arash Arya
Journal:  Circulation       Date:  2013-11-08       Impact factor: 29.690

7.  Amiodarone versus implantable cardioverter-defibrillator:randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia--AMIOVIRT.

Authors:  S Adam Strickberger; John D Hummel; Thomas G Bartlett; Howard I Frumin; Claudio D Schuger; Scott L Beau; Cynthia Bitar; Fred Morady
Journal:  J Am Coll Cardiol       Date:  2003-05-21       Impact factor: 24.094

8.  Catheter ablation of recurrent scar-related ventricular tachycardia using electroanatomical mapping and irrigated ablation technology: results of the prospective multicenter Euro-VT-study.

Authors:  Hildegard Tanner; Gerhard Hindricks; Marius Volkmer; Steve Furniss; Volker Kühlkamp; Dominique Lacroix; Christian DE Chillou; Jesús Almendral; Domenico Caponi; Karl-Heinz Kuck; Hans Kottkamp
Journal:  J Cardiovasc Electrophysiol       Date:  2009-07-28

9.  Wearable cardioverter-defibrillator use in patients perceived to be at high risk early post-myocardial infarction.

Authors:  Andrew E Epstein; William T Abraham; Nicole R Bianco; Karl B Kern; Michael Mirro; Sunil V Rao; Edward K Rhee; Scott D Solomon; Steven J Szymkiewicz
Journal:  J Am Coll Cardiol       Date:  2013-07-31       Impact factor: 24.094

10.  Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy.

Authors:  Alan Kadish; Alan Dyer; James P Daubert; Rebecca Quigg; N A Mark Estes; Kelley P Anderson; Hugh Calkins; David Hoch; Jeffrey Goldberger; Alaa Shalaby; William E Sanders; Andi Schaechter; Joseph H Levine
Journal:  N Engl J Med       Date:  2004-05-20       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.